Wayne does say the $1.4 billion USD NPV is conservatively discounted. I'm sure that factors in the time it will take to get the DurAVR to market and even though he gives an essentially 100% chance of an FDA approval, which I agree with, a discount for the possibility of not getting an FDA approval is likely also included in the NPV calculation just to keep it inline with industry standards. So the NPV is conservatively low. But an attractive buyout will still probably depend on getting the share price up as I wouldn't expect a premium above 200% and most device deals seem to be for less than double the share price.
Also interesting that he says he's in discussions with a bank to do an equity raise so not sure if the bank will offer an equity line of credit or if it could be underwriting the upcoming offering.
And great to hear that the first patients in the EFS have been implanted and the first 2 had a mean gradient of...4! That's amazing. Of course he mentions that the US healthcare system is heavily profit driven. That's why companies all over the world go for the FDA approval, because here in the US we spend 2.3x as much money per patient as Australia and 75% more than the next closest country Germany so the dollars are flowing and that ain't gonna change anytime soon.
Add to My Watchlist
What is My Watchlist?
